SIGILON THERAPEUTICS INC (SGTX) Fundamental Analysis & Valuation

NASDAQ:SGTX • US82657L2060

Current stock price

22.47 USD
-0.59 (-2.56%)
At close:
23 USD
+0.53 (+2.36%)
After Hours:

This SGTX fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

0

1. SGTX Profitability Analysis

1.1 Basic Checks

  • In the past year SGTX has reported negative net income.
  • SGTX had a negative operating cash flow in the past year.
SGTX Yearly Net Income VS EBIT VS OCF VS FCFSGTX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 0 20M -20M -40M -60M -80M

1.2 Ratios

  • SGTX has negative profitability rations, so we won't be analyzing them here.
Industry RankSector Rank
ROA N/A
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
SGTX Yearly ROA, ROE, ROICSGTX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 -500 -1K -1.5K -2K -2.5K

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for SGTX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
SGTX Yearly Profit, Operating, Gross MarginsSGTX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 -200 -400 -600 -800

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

2

2. SGTX Health Analysis

2.1 Basic Checks

  • SGTX does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for SGTX has been increased compared to 1 year ago.
  • SGTX has a worse debt/assets ratio than last year.
SGTX Yearly Shares OutstandingSGTX Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 10M 20M 30M
SGTX Yearly Total Debt VS Total AssetsSGTX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 50M 100M 150M 200M

2.2 Solvency

  • Based on the Altman-Z score of -4.91, we must say that SGTX is in the distress zone and has some risk of bankruptcy.
  • SGTX has a Altman-Z score of -4.91. This is in the lower half of the industry: SGTX underperforms 68.20% of its industry peers.
  • SGTX has a Debt/Equity ratio of 0.31. This is a healthy value indicating a solid balance between debt and equity.
  • SGTX has a Debt to Equity ratio of 0.31. This is in the lower half of the industry: SGTX underperforms 73.64% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.31
Debt/FCF N/A
Altman-Z -4.91
ROIC/WACCN/A
WACC9.94%
SGTX Yearly LT Debt VS Equity VS FCFSGTX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 0 50M -50M 100M

2.3 Liquidity

  • A Current Ratio of 2.23 indicates that SGTX has no problem at all paying its short term obligations.
  • SGTX's Current ratio of 2.23 is on the low side compared to the rest of the industry. SGTX is outperformed by 80.27% of its industry peers.
  • SGTX has a Quick Ratio of 2.23. This indicates that SGTX is financially healthy and has no problem in meeting its short term obligations.
  • Looking at the Quick ratio, with a value of 2.23, SGTX is doing worse than 78.57% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 2.23
Quick Ratio 2.23
SGTX Yearly Current Assets VS Current LiabilitesSGTX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 50M 100M 150M 200M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

3

3. SGTX Growth Analysis

3.1 Past

  • SGTX shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -327.88%.
  • Looking at the last year, SGTX shows a very strong growth in Revenue. The Revenue has grown by 49.27%.
  • The Revenue has been decreasing by -2.95% on average over the past years.
EPS 1Y (TTM)-327.88%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-595.35%
Revenue 1Y (TTM)49.27%
Revenue growth 3Y-2.95%
Revenue growth 5YN/A
Sales Q2Q%53.49%

3.2 Future

  • Based on estimates for the next years, SGTX will show a quite strong growth in Earnings Per Share. The EPS will grow by 13.31% on average per year.
  • SGTX is expected to show a decrease in Revenue. In the coming years, the Revenue will decrease by -0.28% yearly.
EPS Next Y-34.47%
EPS Next 2Y-35.84%
EPS Next 3Y-16.93%
EPS Next 5Y13.31%
Revenue Next Year19.62%
Revenue Next 2Y10.18%
Revenue Next 3Y6.68%
Revenue Next 5Y-0.28%

3.3 Evolution

  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
SGTX Yearly Revenue VS EstimatesSGTX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 5M 10M 15M
SGTX Yearly EPS VS EstimatesSGTX Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 -10 -20 -30 -40 -50

More info and screens

Find the best growth stocksShow best growing peers

0

4. SGTX Valuation Analysis

4.1 Price/Earnings Ratio

  • SGTX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Also next year SGTX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
SGTX Price Earnings VS Forward Price EarningsSGTX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SGTX Per share dataSGTX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 10 -10

4.3 Compensation for Growth

  • A cheap valuation may be justified as SGTX's earnings are expected to decrease with -16.93% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-35.84%
EPS Next 3Y-16.93%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. SGTX Dividend Analysis

5.1 Amount

  • SGTX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Find the best dividend stocksShow peers with best dividend

SGTX Fundamentals: All Metrics, Ratios and Statistics

SIGILON THERAPEUTICS INC

NASDAQ:SGTX (8/10/2023, 8:02:09 PM)

After market: 23 +0.53 (+2.36%)

22.47

-0.59 (-2.56%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-02
Earnings (Next)11-08
Inst Owners0%
Inst Owner Change0%
Ins Owners80.43%
Ins Owner Change0%
Market Cap56.50M
Revenue(TTM)14.64M
Net Income(TTM)-37.08M
Analysts80
Price Target48.28 (114.86%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)23.03%
Min EPS beat(2)0.52%
Max EPS beat(2)45.53%
EPS beat(4)4
Avg EPS beat(4)21.01%
Min EPS beat(4)0.26%
Max EPS beat(4)45.53%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)25.42%
Min Revenue beat(2)-2.79%
Max Revenue beat(2)53.64%
Revenue beat(4)3
Avg Revenue beat(4)32.66%
Min Revenue beat(4)-2.79%
Max Revenue beat(4)66.75%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)1013.72%
EPS NQ rev (1m)0.21%
EPS NQ rev (3m)-1950%
EPS NY rev (1m)-1057.2%
EPS NY rev (3m)-1057.2%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)37.1%
Revenue NY rev (1m)27.67%
Revenue NY rev (3m)27.67%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 3.86
P/FCF N/A
P/OCF N/A
P/B 1.7
P/tB 1.7
EV/EBITDA N/A
EPS(TTM)-9.67
EYN/A
EPS(NY)-13.12
Fwd EYN/A
FCF(TTM)-17.45
FCFYN/A
OCF(TTM)-17.26
OCFYN/A
SpS5.82
BVpS13.24
TBVpS13.24
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA N/A
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.19
Health
Industry RankSector Rank
Debt/Equity 0.31
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 38.88%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.23
Quick Ratio 2.23
Altman-Z -4.91
F-Score2
WACC9.94%
ROIC/WACCN/A
Cap/Depr(3y)106.78%
Cap/Depr(5y)188.85%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-327.88%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-595.35%
EPS Next Y-34.47%
EPS Next 2Y-35.84%
EPS Next 3Y-16.93%
EPS Next 5Y13.31%
Revenue 1Y (TTM)49.27%
Revenue growth 3Y-2.95%
Revenue growth 5YN/A
Sales Q2Q%53.49%
Revenue Next Year19.62%
Revenue Next 2Y10.18%
Revenue Next 3Y6.68%
Revenue Next 5Y-0.28%
EBIT growth 1Y46.93%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year32.02%
EBIT Next 3Y8.16%
EBIT Next 5YN/A
FCF growth 1Y37.49%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y37.23%
OCF growth 3YN/A
OCF growth 5YN/A

SIGILON THERAPEUTICS INC / SGTX Fundamental Analysis FAQ

What is the fundamental rating for SGTX stock?

ChartMill assigns a fundamental rating of 1 / 10 to SGTX.


What is the valuation status for SGTX stock?

ChartMill assigns a valuation rating of 0 / 10 to SIGILON THERAPEUTICS INC (SGTX). This can be considered as Overvalued.


Can you provide the profitability details for SIGILON THERAPEUTICS INC?

SIGILON THERAPEUTICS INC (SGTX) has a profitability rating of 0 / 10.


What is the earnings growth outlook for SIGILON THERAPEUTICS INC?

The Earnings per Share (EPS) of SIGILON THERAPEUTICS INC (SGTX) is expected to decline by -34.47% in the next year.